<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208334</url>
  </required_header>
  <id_info>
    <org_study_id>R119h/61</org_study_id>
    <nct_id>NCT04208334</nct_id>
  </id_info>
  <brief_title>The Effect ofCurcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer</brief_title>
  <acronym>CurChexia</acronym>
  <official_title>A Double-blind, Placebo-controlled Randomized Trial Phase II Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of Curcumin to prevent cancer anorexia and cachexia Syndrom in locally advance and
      advance stage head and neck cancer (stage III, IV)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>60 days after intervention</time_frame>
    <description>We measure muscle mass by Bioelectrical Impedance Analysis (BIA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>60 days after intervention</time_frame>
    <description>We measure BMI by Bioelectrical Impedance Analysis (BIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand grips muscle strength</measure>
    <time_frame>60 days after intervention</time_frame>
    <description>We measure hand grips power by Hand grip test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NF-kB level</measure>
    <time_frame>60 days after intervention</time_frame>
    <description>We measure serum NF-kB by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Cancer Cachexia</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin 4000mg/day x 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo x 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>We give an Intervention arm to consume Curcumin 4000mg/day for 60 consecutive days.</description>
    <arm_group_label>Curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>We give a control arm to consume placebo for 60 consecutive days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Head and neck cancer stage III-IV

          -  Cancer anorexia cachexia syndrome by 2011 Cancer cachexia an International Consensus

          -  Enteral feeding with Nasogastric Tube or Gastrostomy

          -  ECOG 0-2

          -  Normal Bone marrow, kidneys, and liver function

          -  Normal function of enteral digestion and absorption

        Exclusion Criteria:

          -  Pregnancy

          -  History of allergy to Curcumin or herbal medicine

          -  History of Herbal medicine used

          -  History of Billiary of obstruction

          -  History of Antiplatelete or anticoagulant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawasapon Thambamroong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phramongkutklao College of Medicine and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tawasapon Thambamroong, MD</last_name>
    <phone>66944699145</phone>
    <email>T.thambamroong@pmk.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400`</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tawasapon Thambamroong, MD</last_name>
      <phone>6627633325</phone>
      <email>t.thambamroong@pmk.ac.th</email>
    </contact>
    <investigator>
      <last_name>Naiyarat Prasongsuk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014 Nov;14(11):754-62. doi: 10.1038/nrc3829. Epub 2014 Oct 9. Review.</citation>
    <PMID>25291291</PMID>
  </reference>
  <reference>
    <citation>Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, Spiegelman BM. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell. 2001 Nov;8(5):971-82.</citation>
    <PMID>11741533</PMID>
  </reference>
  <reference>
    <citation>Meriggi F. Cancer Cachexia: One Step Ahead. Rev Recent Clin Trials. 2015;10(3):246-50. Review.</citation>
    <PMID>26435290</PMID>
  </reference>
  <reference>
    <citation>Argilés JM, López-Soriano FJ. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci. 1996 Jun;17(6):223-6. Review.</citation>
    <PMID>8763200</PMID>
  </reference>
  <reference>
    <citation>Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care. 2010 May;13(3):225-9. Review.</citation>
    <PMID>20397318</PMID>
  </reference>
  <reference>
    <citation>Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, Busquets S, He J, Kesarwani M, Mindrinos M, Rahme LG, Argilés JM, Tzika AA. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med. 2011 Jan;27(1):15-24. doi: 10.3892/ijmm.2010.557. Epub 2010 Nov 10.</citation>
    <PMID>21069263</PMID>
  </reference>
  <reference>
    <citation>Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Mühlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6.</citation>
    <PMID>27637832</PMID>
  </reference>
  <results_reference>
    <citation>Laviano A, Seelaender M, Sanchez-Lara K, Gioulbasanis I, Molfino A, Rossi Fanelli F. Beyond anorexia -cachexia. Nutrition and modulation of cancer patients' metabolism: supplementary, complementary or alternative anti-neoplastic therapy? Eur J Pharmacol. 2011 Sep;668 Suppl 1:S87-90. doi: 10.1016/j.ejphar.2011.06.060. Epub 2011 Jul 27.</citation>
    <PMID>21810420</PMID>
  </results_reference>
  <results_reference>
    <citation>Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7.</citation>
    <PMID>7424938</PMID>
  </results_reference>
  <results_reference>
    <citation>Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007 Jul;34(1):94-104. Epub 2007 May 23. Review.</citation>
    <PMID>17509812</PMID>
  </results_reference>
  <results_reference>
    <citation>Evans WK, Makuch R, Clamon GH, Feld R, Weiner RS, Moran E, Blum R, Shepherd FA, Jeejeebhoy KN, DeWys WD. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res. 1985 Jul;45(7):3347-53.</citation>
    <PMID>2988769</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013 Apr 20;31(12):1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25.</citation>
    <PMID>23530101</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 Jul-Aug;21(4B):2895-900.</citation>
    <PMID>11712783</PMID>
  </results_reference>
  <results_reference>
    <citation>Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 Jul 15;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024.</citation>
    <PMID>18628464</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer--the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis. 2014 Jun;17(2):180-6. doi: 10.1038/pcan.2014.6. Epub 2014 Mar 11.</citation>
    <PMID>24614693</PMID>
  </results_reference>
  <results_reference>
    <citation>Srivastava DS, Dhaulakhandi DB. Role of NF-KB in Loss of Skeletal Muscle Mass in Cancer Cachexia and its Therapeutic Targets. AJCB. 2013;1(1):16.</citation>
  </results_reference>
  <results_reference>
    <citation>Thaloor D, Miller KJ, Gephart J, Mitchell PO, Pavlath GK. Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol. 1999 Aug;277(2):C320-9. doi: 10.1152/ajpcell.1999.277.2.C320.</citation>
    <PMID>10444409</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta SC, Kim JH, Kannappan R, Reuter S, Dougherty PM, Aggarwal BB. Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood). 2011 Jun 1;236(6):658-71. doi: 10.1258/ebm.2011.011028. Epub 2011 May 12. Review.</citation>
    <PMID>21565893</PMID>
  </results_reference>
  <results_reference>
    <citation>Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res. 2014 Oct;28(10):1461-7. doi: 10.1002/ptr.5149. Epub 2014 Mar 19.</citation>
    <PMID>24648302</PMID>
  </results_reference>
  <results_reference>
    <citation>Busquets S, Carbó N, Almendro V, Quiles MT, López-Soriano FJ, Argilés JM. Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett. 2001 Jun 10;167(1):33-8.</citation>
    <PMID>11323096</PMID>
  </results_reference>
  <results_reference>
    <citation>Siddiqui RA, Hassan S, Harvey KA, Rasool T, Das T, Mukerji P, DeMichele S. Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice. Br J Nutr. 2009 Oct;102(7):967-75. doi: 10.1017/S0007114509345250. Epub 2009 Apr 27.</citation>
    <PMID>19393114</PMID>
  </results_reference>
  <results_reference>
    <citation>Gil da Costa RM, Aragão S, Moutinho M, Alvarado A, Carmo D, Casaca F, Silva S, Ribeiro J, Sousa H, Ferreira R, Nogueira-Ferreira R, Pires MJ, Colaço B, Medeiros R, Venâncio C, Oliveira MM, Bastos MM, Lopes C, Oliveira PA. HPV16 induces a wasting syndrome in transgenic mice: Amelioration by dietary polyphenols via NF-κB inhibition. Life Sci. 2017 Jan 15;169:11-19. doi: 10.1016/j.lfs.2016.10.031. Epub 2016 Nov 22.</citation>
    <PMID>27888116</PMID>
  </results_reference>
  <results_reference>
    <citation>Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003 Feb;9(1):161-8. Review.</citation>
    <PMID>12676044</PMID>
  </results_reference>
  <results_reference>
    <citation>Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489-95. doi: 10.1016/S1470-2045(10)70218-7. Epub 2011 Feb 4. Review.</citation>
    <PMID>21296615</PMID>
  </results_reference>
  <results_reference>
    <citation>Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008 Mar;22(3):659-61. Epub 2007 Oct 17.</citation>
    <PMID>17942826</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer cachexia</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Curcumin</keyword>
  <keyword>Tumuric</keyword>
  <keyword>Cancer anorexia cachexia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

